Pompe disease is a rare genetic disorder that can be inherited from both parents. It affects people all around the world, no matter what age or gender. For many years, scientists and clinicians believed that 1 in 40,000 people were living with Pompe disease. However, as diagnoses increase and newborn screening becomes more common, this estimate is likely to change.
Almost 20 years ago, there were few treatment options for people who developed Pompe disease symptoms. Today, there’s a much greater understanding of how Pompe disease can affect people over time and how it can be managed.
When we share knowledge that helps empower decision making—we Pompe Together.
In Pompe disease, the body is missing or has low levels of an enzyme called “acid alpha-glucosidase” (or GAA). GAA works in tiny cellular compartments called “lysosomes” to break down a complex sugar called “glycogen” into a simple sugar called “glucose.” The body uses glucose for energy.
Pompe disease is a multisystem disorder that has varying rates of progression, age of onset, organ involvement, symptoms, and overall severity.
Pompe disease can be different from one person to the next, depending on the type of GAA gene someone inherits. This gene can influence the amount of functioning GAA a person has in their body—as well as when their symptoms are noticeable and how quickly those symptoms progress.
Pompe disease can be detected at birth in states where newborn screenings test for the disease. It can also be diagnosed when babies younger than 12 months develop symptoms; this type of Pompe disease is called IOPD.
In IOPD, babies may have less than 1% of functioning GAA in cells, resulting in symptoms that may appear within one to three months of life and become serious quickly. These babies need treatment right away in order to survive.
Symptoms may vary but can include:
LOPD, or delayed-onset Pompe disease, refers to people who are diagnosed at any age from early childhood throughout adulthood. In LOPD, someone may have anywhere from about 1% to 30% of functioning GAA in their cells.
Lower levels of functioning GAA can cause symptoms that appear earlier in life and progress faster than in people with higher levels of GAA.
The most common symptoms of Pompe disease are weakness in muscles that control movement and breathing problems that become more difficult over time. Other parts of the body can be affected, too.
The earlier someone is diagnosed with Pompe disease, the sooner they can get the right treatment. Newborns with IOPD are often diagnosed within the first few months of life based on signs, symptoms, and the results of laboratory testing. In older children and adults, diagnosis can take much longer.
Some states and countries offer screening for Pompe disease at birth. In other cases, getting a correct diagnosis can take years—and many doctor visits—for children and adults with LOPD. There are two big reasons for this delay:
1. The disease is very rare and it’s not top of mind for some doctors.
2. Some of the symptoms of Pompe disease are signs of other, more common conditions. In fact, up to about 50% of people with Pompe disease are incorrectly diagnosed with something else first.
Going to a treatment center that specializes in rare diseases may help someone with puzzling symptoms get a diagnosis sooner.
Here’s a list of places to start.
Once a doctor thinks someone might have Pompe disease, the tests to diagnose it are fairly straightforward.
A chest x-ray and electrocardiogram (ECG) may be used to look for signs of heart disease in possible cases of infantile-onset Pompe disease.
Because of the many challenges that go along with Pompe disease, it often helps to have a team of doctors, therapists, and counselors to support patients and their caregivers.
Today, the main treatment for Pompe disease is enzyme replacement therapy (ERT). By replacing the missing GAA enzyme, ERT can help to stop the buildup of glycogen and slow down progressive muscle weakness. ERT is given to patients through an intravenous (into the vein) infusion every other week.
ERT has helped children with infantile-onset Pompe disease live longer. Most people with the late-onset form experience slowed progression while using ERT, although the benefits of treatment may go away over time.
One challenge with ERT is that it can’t always reach all the places in the body that need help. Another issue is that some people develop an immune system reaction that fights the treatment and makes it less effective.
Even with ERT, some people may continue to have symptoms and may experience disease progression over time.
For people with Pompe disease, there are extra treatments that can help. These treatments are designed to meet each person’s specific needs.